K4 Elite
K4 Elite
Thymulin is a zinc-dependent nonapeptide hormone secreted by thymic epithelial cells, studied for its roles in T-cell differentiation and neuroendocrine-immune signaling.
Thymulin, historically termed serum thymic factor (FTS), is a nonapeptide hormone produced by the epithelial cells of the thymus. Its biological activity is strictly dependent on the presence of a coupled zinc ion; the zinc-bound form (zinc-thymulin) is the active species, while the metal-free apopeptide is described in the literature as inactive.
The peptide was among the first thymic factors to be chemically characterized, and it has been used extensively as a model molecule for studying how the thymus contributes to T-lymphocyte maturation and to the broader dialogue between the endocrine and immune systems.
Because circulating thymulin activity declines with age and with zinc deficiency, researchers have examined it as a marker and modulator of thymic function in aging, nutrition, and neuroendocrine-immune studies.
Thymulin's activity requires coordination of a zinc ion, which studies report is necessary for the peptide to adopt its active conformation and to bind high-affinity sites on target lymphocytes. Experimental reports describe zinc-thymulin promoting markers of T-cell differentiation and modulating the balance of T-cell subsets in culture and in animal models.
Additional research describes neuroendocrine interactions, including reported effects on the hypothalamic-pituitary axis and anti-inflammatory and analgesic activity in rodent models, effects investigators attribute in part to modulation of cytokine signaling.
Dardenne and Bach and colleagues, in foundational work characterizing serum thymic factor (reviewed in Dardenne et al., PNAS 1982), established the strict zinc requirement of thymulin by demonstrating that removal of zinc abolished measurable biological activity in bioassays and that reconstitution with zinc restored it.
Safieh-Garabedian and colleagues reported in rodent models (e.g., British Journal of Pharmacology, 1990s) that thymulin administration reduced hyperalgesia and pro-inflammatory cytokine levels in experimental inflammation, describing dose-ranging exposures in the animal models studied rather than any human protocol.
Reggiani and colleagues (2009) reviewed rodent studies in which peripherally administered thymulin or thymulin analogues modulated neuroinflammatory and neuroendocrine endpoints, again as experimental exposures in laboratory animals.
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
References are being compiled for this entry.